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Abstract: Equine influenza (EI) outbreaks occurred on 19 premises in Ireland during 2014.
Disease affected thoroughbred (TB) and non-TB horses/ponies on a variety of premises including four
racing yards. Initial clinical signs presented on 16 premises within a two-month period. Extensive
field investigations were undertaken, and the diagnostic effectiveness of a TaqMan RT-PCR assay
was demonstrated in regularly-vaccinated and sub-clinically-affected horses. Epidemiological data
and repeat clinical samples were collected from 305 horses, of which 40% were reported as clinically
affected, 39% were identified as confirmed cases and 11% were sub-clinically affected. Multivariable
analysis demonstrated a significant association between clinical signs and age, vaccination status
and number of vaccine doses received. Vaccine breakdown was identified in 31% of horses with
up to date vaccination records. This included 27 horses in four different racing yards. Genetic
and antigenic analysis identified causal viruses as belonging to Clade 2 of the Florida sublineage
(FCL2). At the time of this study, no commercially available EI vaccine in Ireland had been updated
in line with World Organisation for Animal Health (OIE) recommendations to include a FCL2 virus.
The findings of this study highlight the potential ease with which EI can spread among partially
immune equine populations.
Keywords: equine influenza Clade 2; TaqMan RT-PCR; vaccination breakdown; thoroughbred
racehorses
1. Introduction
Despite a comprehensive government-funded surveillance programme, mandatory vaccination of
mobile equine populations and annual World Organisation for Animal Health (OIE) recommendations
regarding vaccine composition, equine influenza (EI) remains one of the principal respiratory diseases
affecting horses in Ireland, as it is in many countries around the world. Virus strains circulating in
Europe during the past decade have primarily been identified as Clade 2 of the Florida sublineage
of the American lineage (FCL2) [1–8]. Outbreaks involving Clade 1 (FCL1) viruses have also been
identified, however, to a more limited extent [1–3,6,7]. The failure of companies to update vaccines
with epidemiologically-relevant virus strains facilitates disease spread even among well-vaccinated
populations [9–13]. This, in conjunction with other host and environmental risk factors, results in
a potential threat to equine industries in countries where participation in equestrian events is of
fundamental economic importance.
In Ireland, the majority of non-thoroughbred (non-TB) leisure horses and ponies are not vaccinated.
This is in contrast to sport horses competing at Fédération Equestre Internationale (FEI) events and the
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thoroughbred (TB) racehorse population where mandatory vaccination policies have been in place
since 1981. The focus of this study was to carry out a detailed epidemiological examination of EI
activity in Ireland in 2014 when the virus affected more premises, both non-TB and TB, than any other
outbreak since the turn of the century. This involved extensive investigations on affected premises
with particular emphasis on the identification of host and epidemiological factors, which may have
contributed to virus spread and subsequent vaccine breakdown among horses in TB racing yards.
Furthermore, this study also sought to examine the diagnostic effectiveness of a TaqMan RT-PCR assay
in a partially-immune population.
2. Results
2.1. Overview
Equine influenza was diagnosed on three premises between 30 January and 17 February 2014
and on a further 16 premises between 22 October 2014 and 7 January 2015 (Table 1, Figure 1).
Disease occurred among non-TB horses/ponies and TB horses on a variety of premises including
four racing yards. Outbreaks affected premises in eight different counties with multiple outbreaks
in some counties (Wexford n = 2, Tipperary n = 2, Kildare n = 2, Kilkenny n = 2, Clare n = 3, Meath
n = 6). Farm investigations involving 305 horses on 18 of the 19 premises affected were undertaken.
Serial collection of clinical samples was carried out on average every 7.2 ± 0.44 SE days on up to
five occasions (average three samplings per premises). Of the 305 horses, 121 (40%) were reported
clinically affected by the person responsible for the day to day management of the horses, 118 (39%)
were identified as confirmed cases and 33 (11%) were sub-clinically affected.
Figure 1. Number of premises and population affected from the week commencing 15 October 2014.
TB, thoroughbred.
Pathogens 2018, 7, 43 3 of 16
Table 1. Equine influenza activity in Ireland 2014.
PID Date Location(County)
Method of Case
Confirmation Premises Type
Veterinary
Intervention
Clinical
Cases (%)
Confirmed
Cases (%)
Up to Date Vaccination
Records Available (%)
1 January 2014 Wexford P 6, PS 2 Non-TB 14 days 14/14(100%)
8/14
(57%)
0/14
(0%)
2 February 2014 Wexford P 3, PS 1 Mixed non-TB 14 days 4/5(80%)
4/5
(80%)
1/5
(20%)
3 February 2014 Louth P 9, S 3, PS 2 Equestrian centre/livery yard 3 days 5/29(17%)
14/29
(48%)
1/29
(3%)
4 October 2014 Meath P 3 Non-TB 7 days 3/3(100%)
3/3
(100%)
0/3
(0%)
5 November 2014 Tipperary S 1, PS 4 Mixed non-TB 5 days 5/7(71%)
5/7
(71%)
0/7
(0%)
6 November 2014 Tipperary P 2, S 2, PS 5, PSV 1 Mixed non-TB 2 days 5/16(31%)
10/16
(63%)
6/16
(38%)
7 November 2014 Clare S 1, PS 1 Show jumping 4 days 3/13(23%)
2/13
(15%)
4/13
(31%)
8 November 2014 Kildare P 1, PSV 1 TB (mixed ages and disciplines) 1 day 2/5(40%)
2/5
(40%)
5/5
(100%)
9 November 2014 Clare PS 2 TB (mixed ages and disciplines) 17 days 12/30(40%)
2/30
(7%)
0/30 (0%) (18/30 reported
vaccinated) *
10 December 2014 Kildare PS 1 TB public stud 3 days 3/3(100%)
1/3
(33%)
0/3
(0%)
11 December 2014 Clare PS 2, PSV 1 Non-TB 8 days 3/4(75%)
3/4
(75%)
0/4
(0%)
12 December 2014 Meath P 1 Non-TB 5 days 1/1(100%)
1/1
(100%)
0/1
(0%)
13 December 2014 Dublin P 6, S 2, PS 3 Equestrian centre/livery yard 16 days 8/32(25%)
11/32
(34%)
1/32
(3%)
14 December 2014 Kilkenny P 4, S 1, PS 2, PV 2, PSV 2 Racing yard/TB breeding farm 2 days 13/25(52%)
11/25
(44%)
10/25
(40%)
15 December 2014 Meath P 7 Riding school/livery yard 10 days 6/19(32%)
7/19
(37%)
0/19
(0%)
16 December 2014 Meath P 16, PS 1, PV 1 Racing yard 2 days 17/47(36%)
18/47
(38%)
41/47
(87%)
17 December 2014 Meath P 5, PV 1 Racing yard 6 days 3/13(23%)
6/13
(46%)
10/13
(77%)
18 December 2014 Meath P 4 Mixed non-TB 17 days 2/6(33%)
4/6
(67%)
0/6
(0%)
19 January 2015 Kilkenny P 3, S 2, PS 1 Racing yard 21 days 12/33(36%)
6/33
(18%)
19/33
(58%)
Data presented include premises’ number = PID, date of diagnosis, location, method of case confirmation (P = RT-PCR positive, S = seroconverted, PS = RT-PCR positive and seroconverted,
PV = RT-PCR positive and virus isolated, PSV = RT-PCR positive, seroconverted and virus isolated), type of premises, period before veterinary intervention following the onset of clinical
signs in the index case, number of clinical cases, number of confirmed cases and vaccination status. Mixed = horses and ponies; * = no passports available.
Pathogens 2018, 7, 43 4 of 16
2.2. Diagnosis
Veterinary intervention was sought on average 8.3 ± 1.45 SE days after the onset of clinical signs.
Where veterinary intervention was ≤7.2 ± 1.17 SE days, a positive correlation between confirmed
cases and the incidence of clinical signs was established (p = 0.001). Where no correlation existed,
a significant delay in veterinary intervention was noted (≥12.5 ± 1.89 SE days).
Initial diagnosis on all premises was made by real-time RT-PCR using a primer probe-based assay
on an ABI 7500 thermal cycler platform [14]. Retrospective testing of 1111 nasopharyngeal swabs
collected during previous outbreaks in Ireland (2007–2012) demonstrated that this assay had equivalent
specificity to a LightCycler SYBR Green assay [15] originally used for diagnostic testing [4,16]. However,
an increase in assay sensitivity was demonstrated using the primer probe assay, when 32% of the
1111 nasopharyngeal swabs were identified as RT-PCR positive compared to 16% when using the
LightCycler SYBR Green assay. Discordant samples generally had high cycle threshold (Ct) values,
thus suggesting that the TaqMan assay was of superior sensitivity for the detection of low levels of
viral nucleic acid (data not shown). These results were not considered to be false positives as the
diagnostic specificity of the TaqMan assay was determined by the testing of 250 nasopharyngeal swabs
from populations of horses free of equine influenza. No RT-PCR-positive results were obtained in
these uninfected horses (data not shown).
Seven hundred and twenty six nasopharyngeal swabs were collected from 305 horses during this
study. One hundred and thirty five of the 726 (19%) nasopharyngeal swabs collected tested positive
by RT-PCR. Thirty four of the 135 (25%) were collected from 28 horses with an up to date vaccination
record in accordance with the Turf Club rules and the vaccine manufacturers’ recommendations, i.e.,
a primary course of three vaccinations and subsequent boosters at not more than 12-month intervals. Of the
RT-PCR-positive horses identified, those with no or incomplete vaccination records tested positive 1.4±
0.06 SE times and vaccinated horses tested positive 1.2± 0.09 SE times during consecutive weekly sampling.
Virus isolation was attempted on 29 nasopharyngeal swabs with a Ct value ≤28, and virus was
isolated from 10 (34%). The average Ct value of nasopharyngeal swabs from which virus was isolated
was 22.7 ± 0.99 SE (range 18–26). Eight of the 10 viruses were isolated on the first passage. Four of the
10 viruses were isolated from three horses with up to date vaccination histories. Virus was isolated on
two occasions during a 72-h period from a vaccinated four-year-old gelding. This horse had received
its fourth vaccine dose to five months prior to developing clinical signs and was the index case in the
first TB premises affected during the outbreak (Premises 8).
2.3. Factors Contributing to Disease Spread
All outbreaks occurred during the winter or autumn months and primarily following the return of
horses from an equestrian event or the introduction of a new arrival. The suspected sources of infection
were local hunt meets (seven premises), a visit to an equestrian centre/livery yard (two premises),
a race meeting (one premises) and an international show (one premises). Outbreaks also occurred
following the introduction of a new arrival on five premises. Three of these premises introduced
young TB horses from public sales. There was no significant difference observed in the average period
between exposure to the suspected source and onset of clinical signs on premises where the outbreak
had occurred following recent movement (2.5 ± 0.37 SE days) or following the introduction of a new
arrival (2.0 ± 0.55 SE days). Of the 16 premises from which the likely source of infection was identified,
the travelling horse was the index case in 14.
The average age of horses included in this study was 6.3 ± 5.4 SE years. Clinically-affected horses
ranged from 6 months–16 years of age. Multivariable analysis demonstrated a significant difference
between the age of horses that were clinically affected (4.2 ± 3.6 SE years) compared to those that
remained healthy (7.5 ± 5.9 SE years) (p < 0.001). No association between gender and the incidence of
clinical signs was established.
The vaccination status of horses on each of the 19 premises is summarised in Table 1. A significant
association between clinical signs and vaccination status (p < 0.001) was established. Two hundred
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and seven of the 305 (68%) horses in this study were unvaccinated or had an out of date vaccination
history, of which 91 (44%) developed clinical signs. Of 98 horses that had up to date vaccination
records, clinical signs were observed in 30 (31%). Vaccination breakdown was observed among horses
last vaccinated with all four commercially available products (Table 2). No significant difference in
vaccine product or time since last vaccination was identified. However, in vaccinated horses, there was
a significant association between the absence of clinical signs and the total number of vaccine doses
they had received prior to the outbreak (p = 0.035).
Table 2. Equine influenza vaccine breakdown observed in horses with up to date vaccination records.
Last Vaccine Dose
(Manufacturer)
No. of
Horses (%)
Vaccine
Breakdown (%)
No. of Days
Since V2
No. of Days Since V3
or Subsequent
Booster
Representative H3N8
American Lineage
Vaccine Strain
Duvaxyn IET Plus
(Elanco Animal Health)
43
(44%)
13/43
(30%)
124
(n = 1)
276 ± 27.7 SE
(n = 12) A/eq/Newmarket/1/93
Equip FT
(Zoetis)
10
(10%)
5/10
(50%)
189
(n = 1)
267 ± 51.2 SE
(n = 4) A/eq/Kentucky/98
Equilis Prequenza Te
(MSD Animal Health)
32
(33%)
9/32
(28%)
135 ± 33.5 SE
(n = 2)
217 ± 35.7 SE
(n = 7)
A/eq/South
Africa/4/03 1
ProteqFlu Te
(Merial)
13
(13%)
3/13
(23%)
42
(n = 1)
257 ± 95.5 SE
(n = 2) A/eq/Ohio/03
2
Total/average 98 30/98(31%)
125 ± 25.9 SE
(n = 5)
261 ± 19.6 SE
(n = 25)
No. = number; No. of days since V2 = the number of days since the horse received the second dose of the primary
vaccination. No. of days since V3 = the number of days since the horse received the third dose of the primary
vaccination. 1 Equilis Prequenza updated vaccine became available in Ireland in 2013 and includes Clade 1 Florida
sublineage of the American lineage (FCL1) representative vaccine strain A/eq/South Africa/4/03 (previously
contained A/eq/Newmarket/1/93). 2 ProteqFlu updated vaccine became available in Ireland in December 2014
and includes recombinant canarypox viruses expressing the haemagglutinin gene of A/eq/Ohio/03 (FCL1) and
A/eq/Richmond/1/07 (FCL 2).
2.4. Serological Data
Serial samples were collected from 248 of the 305 (81%) horses included in this study. Sixty of the
248 horses, the majority of which were located on Premises 14 and 16, received booster vaccinations in
the face of the outbreak and thus were excluded from the analysis of seroconversions. Of the remaining
188, 35 (19%) seroconverted to the FCL2 virus A/eq/Meath/1/07 by single radial haemolysis
(SRH) and 27 (14%) seroconverted by haemagglutination inhibition (HI). Twenty four (13%) horses
seroconverted in both tests. Twenty six (14%) horses that seroconverted by one or both methods tested
RT-PCR positive. Of 43 horses that were RT-PCR positive and failed to seroconvert, 41 had a mean
SRH antibody level of 191.3 ± 7.29 SE mm2 on initial sampling. Thus, these samples were probably
collected after exposure to virus and post seroconversion.
Virus Characterisation
The complete HA gene sequence for 27 viruses identified on 13 of the 19 premises was determined
in addition to the partial sequence obtained for a further two viruses (Figure 2, Figure S1). Analysis of
the sequence data indicated that all viruses belonged to FCL2. All viruses had conserved amino acid
substitutions P103L, V112I, A144V (antigenic site A), E291D, V300I in the HA1 gene when compared to
A/eq/Meath/1/07 (Table 3). With the exception of V300I, all substitutions have been observed among
EI viruses previously identified in Ireland [3,4]. V300I, not previously identified among Irish viruses,
was noted among EI viruses, which circulated in the U.K. in 2013 [8]. Within the Irish viruses, a further
two amino acid substitutions occurred in the HA1 gene (S6N, R208G), each on a single premises.
Amino acid substitution S6N was shared among the final five of eight viruses identified on Premises
14 (including two viruses with partially-sequenced HA genes). This change was first observed in a
nasopharyngeal swab collected from a subclinically-affected three-year-old TB gelding nine days after
the onset of clinical signs in the index cases. This horse subsequently developed clinical signs within
24 h of sample collection. This amino acid substitution, not present in the initial three viruses identified
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on this premises or previously in any other Irish virus was observed in FCL1 viruses responsible for
the first EI outbreak in Malaysia in nearly 40 years (A/eq/Malaysia/M201-1/2015, A/eq/Malaysia/
M201-2/2015) [17]. R208G was observed in a single EI virus identified in a racing yard in Co. Meath
(Premises 16). This substitution, located at antigenic site D [18], was not previously been reported to
the best of the authors’ knowledge.
Figure 2. Phylogenetic tree of HA1 nucleotide sequences. Phylogenetic analysis of HA1 nucleotide
sequences encoded by equine influenza viruses. The maximum likelihood tree was created by
Mega Version 6. Bootstrap values were obtained after 1000 replicates and are shown at major
nodes. Phylogenetic groups are shown by continuous bars on the right, as indicated. Representative
viruses from each of the 13 premises on which HA sequence data were obtained are included.
A/eq/Kilkenny/1/14 and A/eq/Kilkenny/4/14 were identified on a single premises.  represents
the strains included in the vaccines.
Pathogens 2018, 7, 43 7 of 16
Table 3. Amino acid substitutions within the HA1 and HA2 genes between viruses identified and the
Irish FCL2 representative virus A/eq/Meath/1/07.
HA1 HA2
Animo Acid Number 6 103 112 144 208 291 300 113 187 199 204
A/eq/1/Meath/07 S P V A R E V A L C G
A/eq/Wexford/14 . L I V . D I T M . .
A/eq/Louth/14 . L I V . D I T M . .
A/eq/Meath/1/14 . L I V . D I . M . S
A/eq/ Tipperary/1/14 . L I V . D I . M Y .
A/eq/Tipperary/3/14 . L I V . D I . M . .
A/eq/ Clare/1/14 . L I V . D I . M . .
A/eq/Kildare/1/14 . L I V . D I . M . .
A/eq/Clare/2/14 . L I V . D I . M . .
A/eq/ Kilkenny/1/14 * . L I V . D I . M . .
A/eq/Kilkenny/4/14 * N L I V . D I . M . .
A/eq/Meath/4/14 . L I V . D I . M . .
A/eq/Meath/5/14 . L I V G D I . M . .
A/eq/Meath/6/14 . L I V . D I . M . .
A/eq/Kilkenny/1/15 . L I V . D I . M . .
The table includes representative viruses from each of the 13 premises on which HA sequence data were obtained.
Amino acid residues are numbered from the serine residue immediately downstream of the predicted signal
sequence. Amino acid identity to the Irish FCL2 representative virus A/eq/Meath/1/07 is shown with a dot. *
A/eq/Kilkenny/1/14 and A/eq/Kilkenny/4/14 were identified on the same premises.
Within the HA2 gene, all viruses in this study had the conserved amino acid substitution
L187M compared to A/eq/Meath/1/07 (Table 3). A further three amino acid changes in
the HA2 were observed within the Irish viruses. A113T occurred in A/eq/Wexford/14, and
A/eq/Louth/14. C199Y was observed in two viruses identified in Tipperary (A/eq/Tipperary/1/14,
A/eq/Tipperary/2/14), while G204S was observed in three viruses identified in Meath
(A/eq/Meath/1/14, A/eq/Meath/2/14, A/eq/Meath/3/14) (Figure S1). With the exception of
C199Y, all amino acid changes have previously been reported [8].
Due to the high level of vaccine breakdown observed during the outbreak, phylogenetic
analysis of the second major surface glycoprotein neuraminidase (NA), for 9 viruses identified
on 8 of the 19 premises along with historic Irish FCL2 (A/eq/Meath/1/07, A/eq/Down/1/08,
A/eq/Kildare/4/10, A/eq/Carlow/11, A/eq/Kildare/2/12, A/eq/Kilkenny/1/12) and FCL1
viruses (A/eq/Limerick/3/10), identified during previous outbreaks, was also performed (Figure 3,
Supplementary Figure S2). Similar to the HA gene, the topology of the NA phylogenetic tree
grouped all recent viruses identified during this study within FCL2 and displayed clear separation
between the pre-divergent, European, American and FCL1 sublineages. Conserved substitutions at
residues 25, 42, 109, 410, 415 and 434 were observed in current circulating viruses when compared to
A/eq/Meath/1/07 (Table 4). All of these changes have previously been reported among EI viruses
circulating in the U.K. [5,8]. Additional substitutions within Irish viruses were also identified at
residues 12 (A/eq/Kilkenny/1/14, A/eq/Kilkenny/4/14) and 22 (A/eq/Kildare/1/14). S12F was
previously observed in the historic FCL2 virus A/eq/Newmarket/5/03 [5,9]. Amino acid substitution
V22I has been reported among FCL2 viruses circulating in the U.K. [8] and Kazakhstan [19].
Antigenic characterisation with strain-specific ferret antisera confirmed the classification of
A/eq/Clare/2/14 as belonging to FCL2 (Table 5). This virus exhibited more than a four-fold greater
antibody titre when tested using FCL2 antisera compared to when using antisera raised against FCL1
viruses. The lowest antibody titres were observed using antisera raised against the European reference
virus A/eq/Newmarket/2/93.
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Figure 3. Phylogenetic tree of NA nucleotide sequences. Phylogenetic analysis of NA nucleotide
sequences encoded by equine influenza viruses. The maximum likelihood tree was created by
Mega Version 6. Bootstrap values were obtained after 1000 replicates and are shown at major
nodes. Phylogenetic groups are shown by continuous bars on the right, as indicated. Representative
viruses from each of the eight premises on which NA sequence data were obtained are included.
A/eq/Kilkenny/1/14 and A/eq/Kilkenny/4/14 were identified on a single premises.  represents
strains included in the vaccines.
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Table 4. Amino acid substitutions within the NA gene between viruses identified and the Irish FCL2
representative virus A/eq/Meath/1/07.
NA
Animo Acid Number 12 22 25 42 109 410 415 434
A/eq/Meath/1/07 S V H G R I K T
A/eq/Meath/1/14 . . N C K V R S
A/eq/Tipperary/1/14 . . N C K V R S
A/eq/Tipperary/3/14 . . N C K V R S
A/eq/Kildare/1/14 . I N C K V R S
A/eq/Clare/2/14 . . N C K V R S
A/eq/Kilkenny/1/14 * F . N C K V R S
A/eq/Kilkenny/4/14 * F . N C K V R S
A/eq/Meath/4/14 . . N C K V R S
A/eq/Meath/5/14 . . N C K V R S
Includes representative viruses from each of the eight premises on which NA sequence data were obtained. Amino
acid residues are numbered from the N-terminal methionine located at the beginning of the predicted signal
sequence. Amino acid identity to the Irish FCL2 representative virus A/eq/Meath/1/07 is shown with a dot.
* A/eq/Kilkenny/1/14 and A/eq/Kilkenny/4/14 were identified on the same premises.
Table 5. Antigenic characterisation of the 2014 isolate by haemagglutination inhibition assay using
ferret antisera.
Reference Ferret Antisera
Reference Virus
Strain
A/eq/NM/1/93
Am
A/eq/NM/2/93
Eu
A/eq/SA/4/03
FCL1
A/eq/DL/1/09
FCL1
A/eq/MH/1/07
FCL2
A/eq/KE/2/12
FCL2
A/eq/NM/1/93 181 32 181 256 724 1024
A/eq/NM/2/93 64 256 64 64 256 256
A/eq/SA/4/03 64 32 1448 1024 512 512
A/eq/DL/1/09 256 128 1024 2896 256 256
A/eq/MH/1/07 362 128 181 256 724 512
A/eq/KE/2/12 181 91 128 256 1024 1024
A/eq/Clare/2/14 181 91 128 256 1024 1024
A/eq/NM/1/93 = A/eq/Newmarket/1/93; Am = American lineage; A/eq/NM/2/93 = A/eq/Newmarket/2/93;
Eu = European lineage; A/eq/SA/4/03 = A/eq/SouthAfrica/4/03; FCL1 = Florida sublineage Clade 1;
A/eq/DL/1/09 = A/eq/Donegal/1/09; A/eq/MH/1/07 = A/eq/Meath/1/07; FCL2 = Florida sublineage Clade
2; A/eq/ KE/2/12 = A/eq/Kildare/2/12. Homologous titres are indicated in bold.
3. Discussion
In 2014, there was an increase in influenza activity in Europe, particularly in the U.K. and
Ireland [20]. Equine influenza was identified among horses and ponies on a total of 12 non-TB and
seven TB premises in Ireland. Initial diagnosis was made on three non-TB premises in January and
February. This followed an absence of any confirmed EI activity in Ireland in 2013. During October
and early November, a further four non-TB premises were affected. On 23 November, clinical signs
were observed and EI was diagnosed in a TB four-year-old gelding, which had been vaccinated in
accordance with the Turf Club Rules (Premises 8). This horse was a new arrival on the Curragh in Co.
Kildare where the majority of TB training yards and Ireland’s premier racetrack are located. It had
recently travelled from a non-TB premises in the west of Ireland. A further six TB premises were
affected within the coming weeks including four racing yards. A similar pattern of virus spillover from
non-TB to TB populations was observed in Ireland during a large outbreak in 1989, which originated at
the Royal Dublin Society horse show and spread extensively throughout the country, affecting several
racing yards [21].
The congregation of horses at any equestrian event is conducive to virus spread [4,16,22,23], and in
this outbreak, EI occurred on 11 of 18 premises following attendance at such events. The risk associated
with failing to isolate horses following recent movement or the introduction of a new arrival with an
unknown immunological status [1,2,4,5,16] was evident in all the premises investigated in this study.
Seven of the 11 premises were affected following the attendance of horses at a hunt meeting. Hunting
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has previously been implicated in EI virus spread [4] and may contribute to the seasonal pattern of EI
observed in this and previous outbreaks [16]. The hunting “season” falls between November and April,
and exposure of intrapulmonary airways to cold air [24] coupled with the strenuous physical activity
may increase the horses’ susceptibility to EI [25], a situation exacerbated by the lack of a compulsory
vaccination policy.
Of further concern is that EI occurred on three premises following the attendance of horses at
a TB breeze up sale, an international horse show and a race meeting where up to date vaccination
is required. During 2014 in Ireland, vaccine breakdown was identified in 30 horses vaccinated with
all four commercially available products. This number was significantly higher than the three cases
reported in the U.K. during the same period [8]. Morbidity ranged from 17–100% on the 18 affected
premises investigated. Analysis of passports on non-TB premises indicated that of 149 horses, only 13
(9%) had an up to date vaccination records and 59 (40%) developed clinical signs. The incidence of
clinical signs among TB horses was 62/156 (40%), i.e., identical to that observed among the non-TB
population even though 98/156 (63%) of TB horses included in this study had an up to date vaccination
record. Virological protection in vaccinated horses has been demonstrated to correlate with the degree
of antigenic relatedness between the vaccine strain and the challenge virus [9,26,27]. FCL2 viruses
have been circulating in Europe since 2003 [28], and although FCL1 viruses were identified in Ireland
in 2009 and 2010, only FCL2 viruses have been identified since [3,4]. The current recommendation to
include FCL2 and FCL1 representative viruses in EI vaccines was initially made by the OIE Expert
Surveillance Panel in 2010 [29]. No updated vaccine was available at the time of last vaccination for
horses included in this study. An updated ProteqFlu (Merial) recombinant vaccine expressing the HA
genes of FCL1 (A/eq/Ohio/03) and FCL2 (A/eq/Richmond/07) viruses became available in Ireland
towards the end of 2014 [30].
Analysis of HA sequence data indicated that all viruses identified during the Irish outbreaks
belonged to FCL2. In Europe in recent years, two subpopulations of FCL2 viruses have been identified
with amino acid substitutions at position 144 or 179 in the HAI gene [8]. All viruses characterised in
the current study contained A144V similar to viruses identified during previous Irish outbreaks [4]
and genetically distinct from an I179V group of EI viruses, which have circulated in Germany, Italy
and in some parts of the U.K. [8]. The biological significance of the substitutions merits investigation.
No antigenic difference between these two FCL2 subgroups has been demonstrated using the HI
assay and post-infection ferret antisera [8]. However, this is in contrast to results observed using an
egg-based virus neutralization test and equine antisera raised against the Argentinian lineage vaccine
strain A/eq/La Plata/93 [31].
Both HA and NA are important surface glycoproteins of influenza virus, but the selection of
vaccine strains has traditionally focused only on the HA. Due to the significant increase in vaccine
breakdown observed in the current study, sequence analysis of the NA gene was carried out. Similar to
the results obtained for the HA gene, the NA phylogenetic tree grouped all recent Irish viruses’ within
FCL2. Of note however, the NA of A/eq/Limerick/3/10 a FLC1 [3] virus was grouped within FCL2
NA subgroup, indicating that reassortment had taken place between the clades. Such reassortment
had been reported previously in the U.K. [1,5].
Similar to previous findings, a correlation between age, time since last vaccination and number of
vaccine doses received was also established [4,16]. Maternal antibodies in foals born to seropositive
mares generally persist for up to six months; however, in some cases, these may be more durable [32–34].
In a comparative antibody study, which examined the antibody levels in different equine populations
in Ireland, TB weanlings (age 6–10 months) were identified as the most susceptible [35]. In this study,
virus infection among TB weanlings in Ireland was identified for the first time (Premises 9, 10, 14).
Vaccination of weanlings is currently not a requirement for attendance at TB sales irrespective of
immunological status. Weanlings on two of the three premises had recently arrived from large TB sales
in Ireland (Premises 9) and the U.K. (Premises 10). The index case on both premises was unvaccinated
and seronegative on initial sampling.
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Among vaccinated horses, infection occurred on average 239 ± 19.2 SE days (range 42–364
days), i.e., approximately eight months following last vaccination. This was observed in horses with
an average age of 3.6 ± 0.37 SE years (range 1–8 years). The poor durability of the response of
young horses to vaccination especially early in their vaccination career is well documented [36–38].
Mathematical models based on data derived from experimental challenge studies, as well as field data
indicate that six-month, rather than annual, booster vaccination reduces the risk of EI infection in young
racehorses [39]. Of 25 index cases identified in this study, seven had an up to date vaccination history.
Laboratory testing is necessary to confirm a clinical diagnosis of EI. The real-time RT-PCR
primer probe-based assay was the primary method of diagnosis during this study [14]. This assay
was extensively used to detect EI in naïve horses in Australia in 2007 [40]. The current study
demonstrated its diagnostic effectiveness in seropositive partially-immune and regularly-vaccinated
horses. Twenty five percent of RT-PCR positive nasopharyngeal swabs identified during this study
were collected from horses with up to date vaccination records. Of 135 RT-PCR positive nasopharyngeal
swabs, 125 (93%) had accompanying serum samples. On serological analysis, 22 (18%) horses
were seronegative, and the 103 (82%) seropositive horses had a mean FCL2 SRH antibody level
of 181 ± 4.4 SE mm2. The maximum FCL2 antibody level detected in an RT-PCR positive horse was
297 mm2. These high SRH values were not necessarily representative of the horses’ serological status
pre-infection, but they indicate that RT-PCR is a sensitive diagnostic technique in seropositive horses.
Read et al. (2011) reported that when monitoring immunologically-naïve horses in Australia, virus
was detected by RT-PCR from a single horse for a maximum period of 34 days [41]. The maximum
period for which virus was detected in two unvaccinated horses during the current study was 12 days
(Premises 1 and 3). Both of these horses, a four-year-old gelding and a seven-year-old mare, had FCL2
SRH antibody levels >150 mm2 on initial sampling. On a single premises, virus was detected for a
maximum period of 21 days (Premises 3). On four premises, virus was detected up to one week after
the last seroconversion was identified (Premises 12, 14, 15, 16).
The serological examination of paired acute and convalescent sera for the diagnosis of EI is used
by many laboratories as an adjunct test to RT-PCR/virus isolation. Hemagglutination inhibition assays
are routinely used with detergent-treated viral antigens to improve assay sensitivity. However, SRH
tests with untreated antigens have been shown to be more reproducible between laboratories, and a
strong correlation between SRH antibody level and protection has been established [42–45]. Thus, SRH
is the serological test of choice for measuring vaccine efficacy. Few studies, however, have compared
EI serological techniques during outbreaks [46,47]. Similar to the findings by Morley et al. [46], a good
correlation between the HI and SRH test was observed in this study, although SRH demonstrated
greater diagnostic sensitivity. The use of improved diagnostics greatly contributes to the detection of
subclinical infection with 33 (11%) horses included in this study identified as subclinically affected.
Twenty six subclinically-infected horses were identified by RT-PCR only, six by SRH only and one by
RT-PCR, SRH and HI. Increased detection of subclinically-infected horses, which are shedding virus, is
key to minimizing the risk of introducing EI to naïve populations through the international movement
of horses.
Farm investigations carried out in the current study are a critical component to EI surveillance
programmes. These investigations coupled with detailed examination of vaccination histories are an
important component of the Department of Agriculture, Food and the Marine (DAFM)-funded EI
surveillance programme in Ireland. They offer the opportunity to examine the pattern of disease spread
among different equine populations in real time and provide data to the OIE Expert Surveillance Panel
regarding the viruses circulating in the field and the effectiveness of current vaccines. This study
also facilitated the evaluation of an RT-PCR diagnostic test for the detection of infection in vaccinated
horses. This is pertinent as recently, the OIE together with the FEI and the International Federation
of Horseracing Authorities (IFHA) has identified EI as one of six OIE listed diseases at risk of
dissemination as a result of international competition horse movements. The availability of EI virus
detection tests that are sufficiently sensitive to detect low quantities of virus shed by vaccinated
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competition horses is considered paramount for screening horses for freedom from infection and
safeguarding not only the horses competing at an international event, but also the population of the
host country.
4. Materials and Methods
4.1. Sample Collection and Clinical Histories
Nasopharyngeal swabs and clotted blood samples were collected from horses with clinical signs
of acute respiratory disease and submitted to the Irish Equine Centre for diagnostic testing. The
nasopharyngeal swabs were custom made for the Irish Equine Centre and after collection were placed
in 5-mL containers of viral transport medium consisting of 4.7 mL phosphate-buffered saline (PBS) at
a dilution of 1:100, 0.1 mL penicillin (5000 u/mL), 0.1 mL amphotericin B (250 mg/ mL) and 0.1 mL
bovine foetal calf serum. Following a confirmed diagnosis of EI and in consultation with the attending
veterinary surgeon/owner, a farm investigation was undertaken. Repeat sampling (nasopharyngeal
swabs and clotted blood samples) of all horses on affected premises was undertaken on a weekly
basis where practical, until all horses tested negative by RT-PCR. Clinical and vaccination histories
were obtained from the attending veterinary surgeon and the personnel involved in the day-to-day
management of the horses. On the premises where EI was diagnosed, morbidity was defined as the
presence of at least one of the three most common clinical signs associated with the virus, i.e., nasal
discharge, coughing and pyrexia [16]. A confirmed case was identified as any horse that tested positive
by at least one of the following methods: RT-PCR, virus isolation and seroconversion [4].
4.2. RNA Extraction and Real-Time RT-PCR
RNA was extracted from 100-µL nasal secretions and 2 µL (20,000 copies) of Xeno RNA
exogenous control with magnetic beads (MagVetTM Universal Purification Kit) using the Kingfisher
Flex 96 magnetic particle processor (Thermo Scientific, Waltham, MA, USA) in accordance with
the manufacturer’s instructions. One-step real-time RT-PCR using a primer probe Spackman-based
assay [14,40,48], which targets the matrix gene of influenza A virus, was carried out on an ABI 7500
Fast thermal cycler platform (Applied Biosystems, Foster City, CA, USA) using an AgPath-ID One-Step
RT-PCR kit (Applied Biosystems, Foster City, CA, USA). Briefly, five microliters of purified nucleic
acid were added to a 20-µL reaction mix containing 2X RT-PCR buffer, 0.08 ng tRNA (Sigma Aldrich,
St. Louis, MO, USA), 0.32 µM of each primer, 0.08 µM of probe, 1 µL Xeno primer/probe assay and
25X RT enzyme and nuclease free H2O. One-step RT-PCR was carried out at 45 ◦C for 10 min, 95 ◦C
for 10 min, followed by 40 cycles of 95 ◦C for 15 s and 60 ◦C for 45 s. Nasopharyngeal swabs with a Ct
value ≤40 were classified as positive.
4.3. Equine Influenza Antibody Detection and Quantification
Antibodies against A/eq/Meath/1/07 (FCL2) were detected by HI in accordance with the
standard procedure [49]. A seroconversion between acute and convalescent samples was defined as a
≥4-fold increase in antibody titre. Antibodies against A/eq/Meath/1/07 were also measured by SRH
as previously described [35]. Results were expressed in mm2, and a seroconversion was defined as a
≥25 mm2 increase in antibody level between paired samples [43]. A horse was designated seronegative
if its serum exhibited no haemolytic activity.
4.4. Virus Isolation
Virus isolation was carried out on all nasopharyngeal swabs that had a Ct value of ≤28. Briefly,
0.1 mL nasopharyngeal secretions at neat, 10−1 and 10−2 dilutions were inoculated into the allantoic
cavity of two 9–12-day-old eggs and incubated at 34 ◦C for 72 h. Eggs were subsequently chilled
overnight (2–8 ◦C) and the allantoic fluid harvested and tested for haemagglutination (HA) activity
using 1% chicken red blood cells [49]. Negative samples were passaged up to four times.
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4.5. Haemagglutinin and Neuraminidase Gene Sequencing
During the outbreak HA and NA gene sequencing was carried out on all nasopharyngeal
swabs, which had a Ct value of ≤30. For historical isolates (A/eq/Meath/1/07, A/eq/Down/1/08,
A/eq/Limerick/3/10, A/eq/Kildare/4/10 and A/eq/Carlow/1/11) where there was insufficient
original sample available, the NA sequencing was performed using low passage (≤3) egg-grown
isolates. Sequencing was performed using a SuperScript III One-Step RT-PCR System with Platinum
Taq High Fidelity (Life Technologies, Carlsbad, CA, USA) in accordance with the manufacturer’s
instructions. Gene specific primers were as follows: HA 5′AGCAAAAGCAGGGGATATTTC,
HA 3′AGTAGAAACAAGGGTGTTTTTAACTATC, NA 5′AGTAGAAACAAGGAGTTTTT, NA
3′AGCAAAAGCAGGAGTTTAAA. Where the full HA gene sequence was not obtainable using
a single primer pair, multiple HA primers were used as previously described [3]. Where the full NA
gene sequence was not obtainable using a single primer pair, sequencing was performed using M13
tagged primers [50]. One-step RT-PCR was carried out at 55 ◦C for 30 min, 94 ◦C for two minutes
followed by 40 cycles of 94 ◦C for 60 s, 45–50 ◦C for 10 s, 60 ◦C for one minute with a final extension
of 60 ◦C for five minutes. RT-PCR products were analysed on a 1% agarose gel stained with SYBR
safe DNA gel stain (Invitrogen, Carlsbad, CA, USA) and purified using the QIAquick gel extraction
kit (Qiagen, Hilden, Germany). Sequencing was performed by Qiagen Sequencing Services (Hilden,
Germany) and GATC Biotech (Konstanz, Germany). Genetic analysis was undertaken using Seqman
Version 5.01 software, DNASTAR, Madison, WI, USA.
4.6. Genetic Sequence Analysis
Maximum likelihood (ML) phylogenetic trees for the nucleotide sequence encoding the HA1
(1009 nt) and the NA (1410 nt) genes were created using MEGA 6.0 software. Genetic distances
were calculated using the Kimura two-parameter model, and statistical support for the tree topology
was assessed by bootstrap resampling (1000 replicates) of the multiple alignments. Nucleotide and
amino acid sequences alignments were constructed using BioEdit software package Version 7.2.5
(Ibis Therapeutics Inc., Carlsbad, CA, USA). All gene sequences included in the phylogenetic analysis
(accession numbers included in Table S1) were obtainable from the NCBI database.
4.7. Antigenic Characterisation
Haemagglutination inhibition testing using Clade-specific ferret antisera generated as previously
described was carried out in accordance with the standard procedure [5]. Briefly, 4 HA units of each
virus were tested with serial dilutions of ferret antisera raised against representative FCL1 (A/eq/South
Africa/4/03 and A/eq/Donegal/1/09) and FCL2 (A/eq/Meath/1/07 and A/eq/Kildare/2/12)
viruses. Each assay was carried out in duplicate and geometric mean titres calculated.
4.8. Statistical Analysis
A multilevel logistic regression model was carried out using open source package R Version 3.1.1
to identify factors that contributed to virus spread. Prevalence factors were analysed as independent
variables, and those with statistical significance (p ≤ 0.05) were included in the model.
Supplementary Materials: The following are available online at http://www.mdpi.com/2076-0817/7/2/43/s1:
Table S1: Equine influenza viruses included in phylogenetic analysis. Figure S1: HA amino acid alignment. Figure
S2: NA amino acid alignment.
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